S

Somnos Clinical Research | Lincoln, NE

Research site
(Unclaimed)
Location
8040 O. Street, Lincoln, Nebraska, United States of America
Site insights

Top conditions

Atopic Dermatitis (3 trials)

Eczema (3 trials)

Dermatitis (3 trials)

Idiopathic Pulmonary Fibrosis (1 trial)

Motor Neuron Disease (1 trial)

Top treatments

Rocatinlimab
AMX0035
TTI-101
AMG 451
Dupilumab
Finerenone
Empagliflozin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 12
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)

The coprimary objectives of the study are to:evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineu...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Enrolling
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Empagliflozin Placebo

The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

Active, not recruiting
Amyotrophic Lateral Sclerosis
Drug: AMX0035
Other: Placebo

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment durat...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: TTI-101
Drug: Placebo

Trial sponsors

Amgen logo

Amgen (3 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems